

New COVID-19 Vaccine Under Emergency Use Authorization as of 7/25/22

The Centers for Disease Control and Prevention (CDC) recently approved the Advisory Committee on Immunization Practices (ACIP) recommendation for the **NOVAVAX COVID-19** vaccine, named NVX-CoV2373.

Key Considerations to Note

- Emergency Use Authorization (EUA) approval has been granted for the primary series for those 18 years of age and older
- **The Novavax vaccine is NOT authorized at this time as a booster shot for itself or other COVID vaccinations**
- Novavax COVID-19 is a protein subunit vaccine; it contains harmless proteins of the COVID virus with an adjuvant that helps the body's immune system respond to the virus in the future
- This mechanism of action has been used for more than 30 years in other vaccines including those for hepatitis B, the flu and whooping cough
- The vaccine does NOT contain eggs, preservatives, latex or metals
- The recommended dosing includes:
 - Two doses in the primary series, administered as an intramuscular injection in the upper arm
 - The second dose is given 3 to 8 weeks after the first dose
 - Immunocompromised individuals should receive 2 doses, 3 weeks apart (3rd dose not yet authorized as of 7/25/22)

Check the Reference Links provided for the most current information.

Reference Links

- [Novavax COVID-19, Adjuvanted Vaccine: Overview and Safety | CDC](#)
- [Novavax Healthcare Provider Fact Sheet | FDA](#)